Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260283 | 0.86 | MEN1 (0.49) | TDP1L3MBTL1MAOBKDM4EMEN1 | |
| SCHEMBL7157499 | 0.86 | MAPT (0.60) | L3MBTL1KDM4EMAPTRAB9AALDH1A1 | |
| SCHEMBL29032428 | 0.85 | MAOB (0.58) | L3MBTL1MAOBLMNAMAPTRAB9A | |
| SCHEMBL11454639 | 0.84 | MAPT (0.60) | TDP1L3MBTL1KDM4EMAPTRAB9A | |
| SCHEMBL8588735 | 0.83 | MAOB (0.53) | L3MBTL1MAOBKDM4EMAPTRAB9A | |
| SCHEMBL6020046 | 0.83 | MAPT (0.68) | TDP1L3MBTL1MAOBLMNAKDM4E | |
| SCHEMBL29032416 | 0.82 | RAB9A (0.48) | MAOBLMNAKDM4EMEN1NPC1 | |
| SCHEMBL5195111 | 0.82 | ALDH1A1 (0.54) | TDP1MAOBLMNAKDM4EMEN1 | |
| SCHEMBL26426649 | 0.82 | KAT6A (0.48) | MAOBLMNAMAPTRAB9AHPGD | |
| SCHEMBL22907155 | 0.82 | MMP3 (0.41) | TDP1L3MBTL1ALDH1A1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | TDP1 892/4885L3MBTL1 1412/4885MAOB 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.